BAYER AG

Discover how Bayer AG’s 2 Sept investor event highlighted modest crop‑science gains, new heart‑and‑kidney drug expansion, and a breakthrough cardiac diagnostic, offering investors a cautious yet forward‑looking outlook amid market volatility.

Discover how Bayer AG’s 2025‑26 earnings, sustainability strides and breakthrough PET imaging for cardiac amyloidosis are reshaping pharma, boosting margins and patient care.

Explore how Bayer AG’s Kerendia expansion in Japan and its $7.25 bn Roundup settlement shape earnings, cost‑effectiveness and patient access for non‑diabetic CKD patients.

Seventh Circuit clears Bayer’s $7.25 B Roundup settlement, ending a 65,000‑claim glyphosate lawsuit and reshaping the company’s legal and financial future.

Discover how Bayer CropScience Limited’s investor event in Mumbai on 2 September 2026 will safeguard transparency while offering insight into its strategy and earnings outlook.

See how Bayer’s shares slipped on DAX’s muted rebound, driven by geopolitical tensions, energy costs, and tightening drug pricing—yet still showing solid financial resilience.

Explore Bayer’s groundbreaking phase‑III cardiovascular, kidney and stroke data revealed at ESC 2026, from finerenone outcomes to new amyloidosis imaging and asundexian stroke prevention.

How Bayer’s postponed $7.25 billion Roundup lawsuit clashes with its crop‑science investor event—and what that means for investors and the DAX.

Explore Bayer AG’s latest investor presentation, spotlighting governance, compliance, and growth strategy—without disclosing financials, yet boosting investor confidence in a shifting regulatory landscape.

Explore Bayer AG’s Q2 results: steady revenue growth, legal win on Roundup, and breakthrough auxin‑based herbicides & oncology drugs. A balanced outlook for investors.